SYNB021225 / Syneron Tech - LARVOL DELTA

SYNB021225: a potent oral pan-KRAS peptide inhibitor that can address unmet needs of small molecule inhibitors (AACR 2025) - "This profile makes SYNB021225 more suitable for combination therapies, such as with anti-PD1 agents, without exacerbating the liver inflammation as seen in the clinic with small molecule inhibitors. Currently, SYNB021225 is being prepared for clinical development."

IO biomarker • Oncology • EGFR • KRAS